This clinical study reveals sex differences in cancer immunotherapy effectiveness in non-small cell lung cancer, suggesting the need for tailored approaches.
Key Points
This research aims to explore how sex differences affect responses to cancer immunotherapy, particularly in non-small cell lung cancer.
Review clinical evidence on sex differences in cancer immunotherapy
Analyze the influence of hormones and genetic factors
Compare responses to mono-immunotherapies and chemo-immunotherapies between sexes
Male patients showed greater benefits from mono-immunotherapies than females in several trials
Females may benefit more from chemo-immunotherapies compared to males
Differences in tumor microenvironment composition were noted but showed varied results across studies
Cite This Study
Krieghoff‐Henning et al. (2026) studied this question.